Clinical Trial Update: Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating reduced-fluence verteporfin photodynamic therapy in combination with ranibizumab for choroidal neovascularization in pathologic myopia;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Pathologic Myopia

Drugs mentioned

• Lucentis (ranibizumab)
• Visudyne (verteporfin)

Snippet

Sponsor: University of Campania Luigi Vanvitelli | Conditions: Myopia, Degenerative | Phase 1 | Status: COMPLETED